Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells

Molecular Oncology

Volumn 7, Issue 4, 2013, Pages 763-775

  Bergadà, Laura ^a   Sorolla, Annabel ^a   Yeramian, Andree ^a   Eritja, Nuria ^a   Mirantes, Cristina ^a   Matias Guiu, Xavier ^a   Dolcet, Xavier ^a  

^a UNIVERSITY OF LLEIDA   (Spain)

Author keywords

Caspase 8; Endometrial cancer; Histone deacetylase inhibitors; Vorinostat

Indexed keywords

BROXURIDINE; CASPASE 8; CASPASE 9; FLICE INHIBITORY PROTEIN; MESSENGER RNA; PROTEIN BCL XL; SHORT HAIRPIN RNA; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME; TUMOR XENOGRAFT; WESTERN BLOTTING;

CASPASE-8; ENDOMETRIAL CANCER; HISTONE DEACETYLASE INHIBITORS; VORINOSTAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 8; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; MICE, SCID; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84880704905     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.03.003     Document Type: Article

References (50)

1. Barbero S., Barila D., Mielgo A., Stagni V., Clair K., Stupack D. Identification of a critical tyrosine residue in caspase 8 that promotes cell migration. The Journal of Biological Chemistry 2008, 283:13031-13034.
2. Barbero S., Mielgo A., Torres V., Teitz T., Shields D.J., Mikolon D., Bogyo M., Barila D., Lahti J.M., Schlaepfer D., Stupack D.G. Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis. Cancer Research 2009, 69:3755-3763.
3. Bodmer J.L., Holler N., Reynard S., Vinciguerra P., Schneider P., Juo P., Blenis J., Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nature Cell Biology 2000, 2:241-243.
4. Borbone E., Berlingieri M.T., De Bellis F., Nebbioso A., Chiappetta G., Mai A., Altucci L., Fusco A. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 2010, 29:105-116.
5. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Letters 2008, 269:7-17.
6. Carlisi D., Lauricella M., D'Anneo A., Emanuele S., Angileri L., Di Fazio P., Santulli A., Vento R., Tesoriere G. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. European Journal of Cancer (Oxford, England: 1990) 2009, 45:2425-2438.
7. Dillon C.P., Oberst A., Weinlich R., Janke L.J., Kang T.B., Ben-Moshe T., Mak T.W., Wallach D., Green D.R. Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Reports 2012, 1:401-407.
8. Dolcet X., Llobet D., Pallares J., Rue M., Comella J.X., Matias-Guiu X. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 2005, 85:885-894.
9. Frew A.J., Lindemann R.K., Martin B.P., Clarke C.J., Sharkey J., Anthony D.A., Banks K.M., Haynes N.M., Gangatirkar P., Stanley K., Bolden J.E., Takeda K., Yagita H., Secrist J.P., Smyth M.J., Johnstone R.W. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:11317-11322.
10. Gaymes T.J., Padua R.A., Pla M., Orr S., Omidvar N., Chomienne C., Mufti G.J., Rassool F.V. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?. Molecular Cancer Research: MCR 2006, 4:563-573.
11. Hagelkruys A., Sawicka A., Rennmayr M., Seiser C. Thebiology of HDAC in cancer: the nuclear and epigenetic components. Handbook of Experimental Pharmacology 2011, 206:13-37.
12. Hurwitz J.L., Stasik I., Kerr E.M., Holohan C., Redmond K.M., McLaughlin K.M., Busacca S., Barbone D., Broaddus V.C., Gray S.G., O'Byrne K.J., Johnston P.G., Fennell D.A., Longley D.B. Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. European Journal of Cancer (Oxford, England: 1990) 2012, 48:1096-1107.
13. Kennedy N.J., Kataoka T., Tschopp J., Budd R.C. Caspase activation is required for T cell proliferation. The Journal of Experimental Medicine 1999, 190:1891-1896.
14. Kerr E., Holohan C., McLaughlin K.M., Majkut J., Dolan S., Redmond K., Riley J., McLaughlin K., Stasik I., Crudden M., Van Schaeybroeck S., Fenning C., O'Connor R., Kiely P., Sgobba M., Haigh D., Johnston P.G., Longley D.B. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death and Differentiation 2012, 19:1317-1327.
15. Kim H.J., Bae S.C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. American Journal of Translational Research 2011, 3:166-179.
16. Kim P.K., Mahidhara R., Seol D.W. The role of caspase-8 in resistance to cancer chemotherapy. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 2001, 4:293-296.
17. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12:611-620.
18. Kuida K., Haydar T.F., Kuan C.Y., Gu Y., Taya C., Karasuyama H., Su M.S., Rakic P., Flavell R.A. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998, 94:325-337.
19. Lamkanfi M., Festjens N., Declercq W., Vanden Berghe T., Vandenabeele P. Caspases in cell survival, proliferation and differentiation. Cell Death and Differentiation 2007, 14:44-55.
20. Lemmers B., Salmena L., Bidere N., Su H., Matysiak-Zablocki E., Murakami K., Ohashi P.S., Jurisicova A., Lenardo M., Hakem R., Hakem A. Essential role for caspase-8 in Toll-like receptors and NFkappaB signaling. The Journal of Biological Chemistry 2007, 282:7416-7423.
21. Llobet D., Eritja N., Domingo M., Bergada L., Mirantes C., Santacana M., Pallares J., Macia A., Yeramian A., Encinas M., Moreno-Bueno G., Palacios J., Lewis R.E., Matias-Guiu X., Dolcet X. KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. The American Journal of Pathology 2011, 178:1529-1543.
22. Llobet D., Eritja N., Encinas M., Llecha N., Yeramian A., Pallares J., Sorolla A., Gonzalez-Tallada F.J., Matias-Guiu X., Dolcet X. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene 2008, 27:2513-2524.
23. Llobet D., Eritja N., Yeramian A., Pallares J., Sorolla A., Domingo M., Santacana M., Gonzalez-Tallada F.J., Matias-Guiu X., Dolcet X. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. European Journal of Cancer (Oxford, England: 1990) 2010, 46:836-850.
24. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. Journal of Cellular Biochemistry 2009, 107:600-608.
25. Matias-Guiu X., Catasus L., Bussaglia E., Lagarda H., Garcia A., Pons C., Munoz J., Arguelles R., Machin P., Prat J. Molecular pathology of endometrial hyperplasia and carcinoma. Human Pathology 2001, 32:569-577.
26. McKee A.E., Thiele C.J. Targeting caspase 8 to reduce the formation of metastases in neuroblastoma. Expert Opinion on Therapeutic Targets 2006, 10:703-708.
27. Nagji A.S., Cho S.H., Liu Y., Lee J.K., Jones D.R. Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Molecular Cancer Therapeutics 2010, 9:2834-2843.
28. Palmieri D., Lockman P.R., Thomas F.C., Hua E., Herring J., Hargrave E., Johnson M., Flores N., Qian Y., Vega-Valle E., Taskar K.S., Rudraraju V., Mittapalli R.K., Gaasch J.A., Bohn K.A., Thorsheim H.R., Liewehr D.J., Davis S., Reilly J.F., Walker R., Bronder J.L., Feigenbaum L., Steinberg S.M., Camphausen K., Meltzer P.S., Richon V.M., Smith Q.R., Steeg P.S. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15:6148-6157.
29. Pei X.Y., Dai Y., Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2004, 10:3839-3852.
30. Petrella A., Fontanella B., Carratu A., Bizzarro V., Rodriquez M., Parente L. Histone deacetylase inhibitors in the treatment of hematological malignancies. Mini Reviews in Medicinal Chemistry 2011, 11:519-527.
31. Petruccelli L.A., Dupere-Richer D., Pettersson F., Retrouvey H., Skoulikas S., Miller W.H. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One 2011, 6:e20987.
32. Sarfstein R., Bruchim I., Fishman A., Werner H. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. PLoS One 2011, 6:e24468.
33. Schwerk C., Schulze-Osthoff K. Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochemical Pharmacology 2003, 66:1453-1458.
34. Shin H., Lee Y.S., Lee Y.C. Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells. Oncology Reports 2012, 27:1111-1115.
35. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., Krammer P.H., Walczak H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000, 12:599-609.
36. Stimson L., Wood V., Khan O., Fotheringham S., La Thangue N.B. HDAC inhibitor-based therapies and haematological malignancy. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2009, 20:1293-1302.
37. Sung E.S., Kim A., Park J.S., Chung J., Kwon M.H., Kim Y.S. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis: An International Journal on Programmed Cell Death 2010, 15:1256-1269.
38. Takai N., Desmond J.C., Kumagai T., Gui D., Said J.W., Whittaker S., Miyakawa I., Koeffler H.P. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2004, 10:1141-1149.
39. Thome M., Schneider P., Hofmann K., Fickenscher H., Meinl E., Neipel F., Mattmann C., Burns K., Bodmer J.L., Schroter M., Scaffidi C., Krammer P.H., Peter M.E., Tschopp J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386:517-521.
40. Torres V.A., Mielgo A., Barbero S., Hsiao R., Wilkins J.A., Stupack D.G. Rab5 mediates caspase-8-promoted cell motility and metastasis. Molecular Biology of the Cell 2010, 21:369-376.
41. Uchida H., Maruyama T., Nagashima T., Asada H., Yoshimura Y. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 2005, 146:5365-5373.
42. Uchida H., Maruyama T., Ono M., Ohta K., Kajitani T., Masuda H., Nagashima T., Arase T., Asada H., Yoshimura Y. Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 2007, 148:896-902.
43. van Raam B.J., Salvesen G.S. Proliferative versus apoptotic functions of caspase-8 hetero or homo: the caspase-8 dimer controls cell fate. Biochimica et biophysica acta 2012, 1824:113-122.
44. Varfolomeev E.E., Schuchmann M., Luria V., Chiannilkulchai N., Beckmann J.S., Mett I.L., Rebrikov D., Brodianski V.M., Kemper O.C., Kollet O., Lapidot T., Soffer D., Sobe T., Avraham K.B., Goncharov T., Holtmann H., Lonai P., Wallach D. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998, 9:267-276.
45. Walker T., Mitchell C., Park M.A., Yacoub A., Graf M., Rahmani M., Houghton P.J., Voelkel-Johnson C., Grant S., Dent P. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Molecular Pharmacology 2009, 76:342-355.
46. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317.
47. Yang Y.T., Balch C., Kulp S.K., Mand M.R., Nephew K.P., Chen C.S. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia (New York, N.Y.) 2009, 11:552-563. 553 pp. following 563.
48. Yeramian A., Moreno-Bueno G., Dolcet X., Catasus L., Abal M., Colas E., Reventos J., Palacios J., Prat J., Matias-Guiu X. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene 2012, 32:403-413.
49. Yerbes R., Lopez-Rivas A. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumor cells to TRAIL. Investigational New Drugs 2012, 30:541-547.
50. Zhang G., Park M.A., Mitchell C., Hamed H., Rahmani M., Martin A.P., Curiel D.T., Yacoub A., Graf M., Lee R., Roberts J.D., Fisher P.B., Grant S., Dent P. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:5385-5399.